- Cardiol Therapeutics (CRDL) has announced the closing of its US$50M public offering
- The company issued 16,350,000 units priced at US$3.07 per unit for gross proceeds of US$50,194,500
- The company will use the proceeds to advance its research and clinical development programs, additional product development and for general corporate purposes
- Cardiol Therapeutics is a clinical stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease
- Cardiol Therapeutics Inc. (CRDL) is down 1.23 per cent, trading at C$3.20 per share at 2:15 pm ET
Cardiol Therapeutics (CRDL) has announced the closing of its US$50M public offering.
The company issued 16,350,000 units priced at US$3.07 per unit for gross proceeds of US$50,194,500.
Each unit is comprised of one Class A common share and one-half of one Class A common share purchase warrant.
Each warrant entitles the holder to purchase one Class A common share for US$3.75 until November 5, 2024.
Canaccord Genuity and Cantor Fitzgerald acted as joint bookrunners.
The company will use the proceeds to advance its research and clinical development programs, additional product development and general corporate purposes.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease.
Cardiol Therapeutics Inc. (CRDL) is down 1.23 per cent, trading at C$3.20 per share at 2:15 pm ET.
